{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:44:10Z","timestamp":1793126650816,"version":"4.5.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007447","name":"Susan Thompson Buffett Foundation","doi-asserted-by":"publisher","award":["3770"],"award-info":[{"award-number":["3770"]}],"id":[{"id":"10.13039\/100007447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002110","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T17:30:39Z","timestamp":1472578239000},"page":"e1002110","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-2157","authenticated-orcid":true,"given":"Ushma D.","family":"Upadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-4582","authenticated-orcid":true,"given":"Nicole E.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Combellick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-0686","authenticated-orcid":true,"given":"Lisa M.","family":"Keder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C. M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.contraception.2003.08.017","article-title":"&quot;Medical&quot; and &quot;surgical&quot; abortion: rethinking the modifiers","volume":"69","author":"TA Weitz","year":"2004","journal-title":"Contraception"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.contraception.2015.06.019","article-title":"Fifteen years: looking back and looking forward","volume":"92","author":"B Winikoff","year":"2015","journal-title":"Contraception"},{"issue":"23","key":"ref3","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1056\/NEJMe1604462","article-title":"A New Label for Mifepristone","volume":"374","author":"MF Greene","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-0528.2000.tb13273.x","article-title":"Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial","volume":"107","year":"2000","journal-title":"BJOG"},{"issue":"18","key":"ref5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199804303381801","article-title":"Early pregnancy termination with mifepristone and misoprostol in the United States","volume":"338","author":"IM Spitz","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002855.pub4","article-title":"Medical methods for first trimester abortion","author":"R Kulier","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"issue":"6903","key":"ref7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/bmj.307.6903.532","article-title":"Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation","volume":"307","year":"1993","journal-title":"Bmj"},{"issue":"2 Suppl","key":"ref8","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1067\/mob.2000.107950","article-title":"Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions","volume":"183","author":"EP Newhall","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2471\/BLT.10.084046","article-title":"Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review","volume":"89","author":"TD Ngo","year":"2011","journal-title":"Bulletin of the World Health Organization"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0010-7824(99)00119-5","article-title":"Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days","volume":"61","author":"EA Schaff","year":"2000","journal-title":"Contraception"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0010-7824(02)00366-9","article-title":"Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy","volume":"66","author":"EA Schaff","year":"2002","journal-title":"Contraception"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0010-7824(01)00229-3","article-title":"Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion","volume":"64","author":"EA Schaff","year":"2001","journal-title":"Contraception"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1363\/3501603","article-title":"The accessibility of abortion services in the United States, 2001","volume":"35","author":"SK Henshaw","year":"2003","journal-title":"Perspect Sex Reprod Health"},{"issue":"4","key":"ref14","first-page":"871","article-title":"Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion","volume":"106","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0b013e31826c315f","article-title":"Extending outpatient medical abortion services through 70 days of gestational age","volume":"120","author":"B Winikoff","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"44","key":"ref16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0968-8080(15)43825-X","article-title":"Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City","volume":"22","author":"Smith P Sanhueza","year":"2015","journal-title":"Reprod Health Matters"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2015.01.005","article-title":"Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days","volume":"91","author":"M Gatter","year":"2015","journal-title":"Contraception"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.AOG.0000444454.67279.7d","article-title":"Practice bulletin no. 143: medical management of first-trimester abortion","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/AOG.0b013e31818d8eb4","article-title":"Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial","volume":"112","author":"B Winikoff","year":"2008","journal-title":"Obstet Gynecol"},{"key":"ref20","unstructured":"National Abortion Federation. NAF Protocol for Mifepristone\/Misoprostol in Early Abortion in the U.S. 2010. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/prochoice.org\/wp-content\/uploads\/protocol_mife_miso.pdf\" xlink:type=\"simple\">http:\/\/prochoice.org\/wp-content\/uploads\/protocol_mife_miso.pdf<\/ext-link>."},{"key":"ref21","unstructured":"World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva, Switzerland: 2012. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/reproductivehealth\/publications\/unsafe_abortion\/9789241548434\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/reproductivehealth\/publications\/unsafe_abortion\/9789241548434\/en\/<\/ext-link>."},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"OFf-label prescribing among office-based physicians","volume":"166","author":"DC Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref23","unstructured":"U.S. Food and Drug Administration. &quot;Off-Label&quot; and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices\u2014Information Sheet. 1998."},{"key":"ref24","unstructured":"U.S. Food and Drug Administration. Mifeprex (mifepristone) Information. Postmarket Drug Safety Information for Patients and Providers: 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm111323.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm111323.htm<\/ext-link>."},{"issue":"1","key":"ref25","article-title":"Medication Abortion Restrictions Burden Women and Providers\u2014and Threaten U.S. Trend Toward Very Early Abortion","author":"HD Boonstra","year":"2013","journal-title":"Guttmacher Policy Review"},{"key":"ref26","unstructured":"ND HB 1297, Legislative Assembly of North Dakota (2011). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.legis.nd.gov\/assembly\/62-2011\/bill-index\/bi1297.html\" xlink:type=\"simple\">http:\/\/www.legis.nd.gov\/assembly\/62-2011\/bill-index\/bi1297.html<\/ext-link>."},{"key":"ref27","unstructured":"TX HB2, Texas State of Representatives (2013). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.legis.state.tx.us\/BillLookup\/History.aspx?LegSess=832&Bill=HB2\" xlink:type=\"simple\">http:\/\/www.legis.state.tx.us\/BillLookup\/History.aspx?LegSess=832&amp;Bill=HB2<\/ext-link>."},{"key":"ref28","unstructured":"Associated Press. New abortion drug label could undo several state laws. March 30, 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.modernhealthcare.com\/article\/20160330\/NEWS\/303309998\" xlink:type=\"simple\">http:\/\/www.modernhealthcare.com\/article\/20160330\/NEWS\/303309998<\/ext-link>."},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/AOG.0000000000000603","article-title":"Incidence of emergency department visits and complications after abortion","volume":"125","author":"UD Upadhyay","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/00016340701203632","article-title":"Risk factors for unsuccessful medical abortion with mifepristone and misoprostol","volume":"86","author":"R Haimov-Kochman","year":"2007","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"MG Kenward","year":"1997","journal-title":"Biometrics"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/oem.2004.017459","article-title":"Poisson regression analysis of ungrouped data","volume":"62","author":"D Loomis","year":"2005","journal-title":"Occupational and environmental medicine"},{"key":"ref33","unstructured":"Bureau of Labor Statistics. Consumer Price Index for Medical Care. 2015."},{"key":"ref34","article-title":"Mifepristone Label Laws and Trends in Use: Recent Experiences in Four U.S. States","author":"WR Sheldon","year":"2015","journal-title":"Contraception"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.contraception.2014.07.006","article-title":"Change in abortion services after implementation of a restrictive law in Texas","volume":"90","author":"D Grossman","year":"2014","journal-title":"Contraception"},{"issue":"11","key":"ref36","first-page":"1","article-title":"Abortion surveillance\u2014United States, 2011","volume":"63","author":"K Pazol","year":"2014","journal-title":"MMWR Surveill Summ"},{"key":"ref37","article-title":"Abortion Incidence and Service Availability In the United States, 2011","author":"RK Jones","year":"2014","journal-title":"Perspect Sex Reprod Health"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2307\/2134696","article-title":"How patients view mandatory waiting periods for abortion","volume":"13","author":"M Lupfer","year":"1981","journal-title":"Fam Plann Perspect"},{"key":"ref39","article-title":"Abortion Restrictions Complicate Access For Ohio Women","author":"J Ludden","year":"2015","journal-title":"NPR"},{"key":"ref40","unstructured":"Gross A. John Kasich\u2019s Quiet Campaign To Cut Abortion Access. FiveThirtyEight. 2015 December 2, 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/fivethirtyeight.com\/features\/john-kasichs-quiet-campaign-to-cut-abortion-access\/\" xlink:type=\"simple\">http:\/\/fivethirtyeight.com\/features\/john-kasichs-quiet-campaign-to-cut-abortion-access\/<\/ext-link>."},{"issue":"7","key":"ref41","first-page":"738","article-title":"Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation","volume":"108","year":"2001","journal-title":"BJOG"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejogrb.2005.02.019","article-title":"Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone","volume":"123","author":"C Arvidsson","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"15","key":"ref43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM199504133321502","article-title":"Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol","volume":"332","author":"H el-Refaey","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-0528.2004.00153.x","article-title":"WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion","volume":"111","author":"H Honkanen","year":"2004","journal-title":"BJOG"},{"issue":"8","key":"ref45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archinternmed.2012.34","article-title":"Health insurance status change and emergency department use among US adults","volume":"172","author":"AA Ginde","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jemermed.2007.09.042","article-title":"A Comparison of Frequent and Infrequent Visitors to an Urban Emergency Department","volume":"38","author":"E Sandoval","year":"2010","journal-title":"J Emerg Med"},{"key":"ref47","unstructured":"U.S. Department of Health &amp; Human Services. Health Insurance Coverage and the Affordable Care Act. 2015."},{"key":"ref48","unstructured":"Siegel J, Candinsky C. Medicaid expansion funding gets approval. The Columbus Dispatch. October 21, 2013. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.dispatch.com\/content\/stories\/local\/2013\/10\/21\/Medicaid-expansion-vote.html\" xlink:type=\"simple\">http:\/\/www.dispatch.com\/content\/stories\/local\/2013\/10\/21\/Medicaid-expansion-vote.html<\/ext-link>."},{"key":"ref49","unstructured":"U.S. Department of Health &amp; Human Services. Key Features of the Affordable Care Act By Year. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hhs.gov\/healthcare\/facts-and-features\/key-features-of-aca-by-year\/index.html\" xlink:type=\"simple\">http:\/\/www.hhs.gov\/healthcare\/facts-and-features\/key-features-of-aca-by-year\/index.html<\/ext-link>. 2015."},{"key":"ref50","unstructured":"House Bill Number 79, General Assembly of the State of Ohio (2012). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/archives.legislature.state.oh.us\/bills.cfm?ID=129_HB_79_PS\" xlink:type=\"simple\">http:\/\/archives.legislature.state.oh.us\/bills.cfm?ID=129_HB_79_PS<\/ext-link>."},{"key":"ref51","unstructured":"Redden M. Abortion without the clinic on offer with revolutionary new US program. The Guardian. 2016 March 31, 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.theguardian.com\/world\/2016\/mar\/31\/new-us-program-abortion-without-clinic-mifepristone-mifeprex\" xlink:type=\"simple\">http:\/\/www.theguardian.com\/world\/2016\/mar\/31\/new-us-program-abortion-without-clinic-mifepristone-mifeprex<\/ext-link>."},{"key":"ref52","unstructured":"Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine [Internet]. National Library of Medicine. 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02513043\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02513043<\/ext-link>."},{"key":"ref53","unstructured":"Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation [Internet]. National Library of Medicine. 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02314754\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02314754<\/ext-link>."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:12:12Z","timestamp":1601053932000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002110"}},"subtitle":[],"editor":[{"given":"Joel G.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002110","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]}}}